Pcn345 - Health State Utilities in Metastatic Nsclc: A Study of Multiple Immuno-Oncology Trials

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.427
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Immunodynamics: A Cancer Immunotherapy Trials Network Review of Immune Monitoring in Immuno-Oncology Clinical Trials

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2016English

Immuno‐Oncology Forum

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

The Role of Radiation Oncology in Immuno‐Oncology

Oncologist
Cancer ResearchMedicineOncology
2019English

Pmu30 - Budget and Health Impact of Immuno-Oncology Treatments in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Mevalonate Metabolism in Immuno-Oncology

Frontiers in Immunology
AllergyImmunology
2017English

Health State Utilities in Patients With Relapsing Remitting Multiple Sclerosis Treated With Cladribine Tablets

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immuno‐oncology for Surgeons

British Journal of Surgery
Surgery
2019English

Immuno-Oncology and Immunotherapy

2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy